Tobacco Regulation Awareness, Communication, And Education Program

 

The purpose of the Program is to assist entities to establish or expand health education and communication programs at the community level that support the goals of current and future FDA tobacco regulations. The Program will advance public health by supporting community-based programs that work to identify and disseminate evidence-based, community-level best practices for tobacco regulation, communication and education, and increase access to standardized, community-level data. Strong applications would seek to educate and communicate to 1) promote the understanding of tobacco product regulation and the consequences of tobacco use; 2) protect youth from the dangers of tobacco use; and 3) help those who use tobacco to quit. Funding recipients must implement a comprehensive public education and/or communication program that addresses federal tobacco regulations and the public health goals which flow directly from them, as identified in the applicant’s needs assessment and that will improve health outcomes for members of target population(s).

Deleted 09/09/2014 (Archived.) 93.058 Agency: Department of Health and Human Services
Office: Food and Drug Administration Cooperative Agreements Not Applicable. 42 USC 300u-3 of the Public Health Service Act and the Family Smoking Prevention and Tobacco Control Act, Public Law 111-31. Applicants should review the eligibility information in the individual funding opportunity announcement issued under this CFDA. The Program will assist entities to establish or expand health education and communication programs at the community level that support the goals of current and future FDA tobacco regulations. The general public will ultimately benefit by becoming educated about the risks of tobacco products so that youth are protected from harmful tobacco exposure, and adults can make informed choices about tobacco use for themselves. Applicants should review the individual funding opportunity announcement issued under this CFDA program for any required proof of certifications which must be submitted prior to or simultaneous with submission of an application. OMB Circular No. A-87 applies to this program. Preapplication coordination is not applicable. Environmental impact information is not required for this program. This program is excluded from coverage under E.O. 12372. OMB Circular No. A-102 applies to this program. OMB Circular No. A-110 applies to this program. It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in the funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review. Applicants are encouraged to submit a non-binding Notice of Intent to Apply. Notices of Intent to Apply are not required and an applicant’s submission or failure to submit a notice has no bearing on the scoring of proposals received. Notices of Intent to Apply are due no later than the date noted in the funding opportunity announcement.
For competitive awards, FDA/CTP will review and evaluate applications, proposals, and/or submissions in accordance with the terms, conditions, and criteria stated in the funding opportunity announcement issued under this CFDA program. Successful applicants will receive a Notice of Award. Unsuccessful applicants will be notified by letter. All FDA awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement. Contact the headquarters or regional office, as appropriate, for application deadlines. From 120 to 180 days. Not Applicable. Throughout the project period, FDA/CTP’s commitment to continuation of awards will be conditioned on the availability of funds, evidence of satisfactory performance and outcomes by the recipient (as documented in required reports and site visit observations), and the determination that continued funding is in the best interest of the Federal Government. Applicants should review the individual funding opportunity announcement issued under this CFDA program for criteria for selecting proposals. The Program’s grant funds would support eligible entities in carrying out their plans to establish or expand health communication and education programs that are congruent with the FDA Tobacco Control Act. Funded communication and education projects would seek to: •Promote the understanding of tobacco product regulation and the consequences of tobacco use; •Protect youth from the dangers of tobacco use; and •Help those who use tobacco to quit. The public education and/or communication program must include the following activities.
(a) Propose a communication/education project that is evidence-based and relies on: •Previous work in the area of tobacco regulation, prevention, and/or cessation; or •Promising or innovative communication/education strategies to advance the public’s health consistent with federal tobacco regulation and the public health goals of the Tobacco Control Act. (b) Collaborate with one State and/or Local governmental entity and at least one community-based partner to identify and implement innovative strategies to help reduce tobacco use and help strengthen and/or sustain new or existing health communication and education infrastructures in the community. (c) Plan, build, adapt, or expand data collection, management, and reporting protocols for program activities. This data will be used by the funding recipient for program monitoring, continuous program improvements, and accountability. (d) Evaluate program processes and outcomes, including formative and summative. Program funds may not be used to duplicate or supplant existing tobacco control, prevention, or cessation efforts, but can enhance existing communication/education efforts relevant to FDA/CTP and the Tobacco Control Act. Funds may not be used to fund other tobacco control areas such as surveillance, price and tax measures, clean indoor air laws, tobacco control compliance and enforcement efforts, and treatment services like quit lines, nicotine replacement therapy, or any other pharmaceutical or biomedical therapy. Funds may not be used to create anti-tobacco industry campaigns. A final program progress report must be submitted within 90 days after the expiration of the project period as noted on the Notice of Grant Award. A final progress report is also required when an award is relinquished, when a recipient changes institutions, or when an award is terminated. The final program progress report must provide full written documentation of the project, and summaries of achievement of project goals, objectives, and performance measures as described in the application. No cash reports are required. For continuing cooperative agreements, an annual progress report is required. Awardees will be required to submit the PHS 2590 annually and financial statements as required in the DHHS Grants Policy Statement. http://www.hhs.gov/asrt/og/grantinformation/hhsgps107.pdf. Financial Status Reports are due at the end of each budget period, and a final Financial Status Report is due 90 days following the end of the project period. The program project officer will monitor funding recipients periodically. The monitoring may be in the form of telephone conversations, e-mails, or written correspondence between the project office/grants management office and the principal investigator. Periodic site visits with officials of the funding recipient organization may also occur. The results of these monitoring activities will be recorded in the official grant file and will be available to the funding recipient upon request consistent with applicable disclosure statutes and with FDA disclosure regulations. Also, the funding recipient organization must comply with all special terms and conditions of the cooperative agreement, including those which state that future funding of the project will depend on recommendations from the project officer. In accordance with the provisions of OMB Circular No. A-133 (Revised, June 27, 2003), "Audits of States, Local Governments, and Non-Profit Organizations," nonfederal entities that expend financial assistance of $500,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Nonfederal entities that expend less than $500,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in Circular No. A-133. Financial records, supporting documents, statistical records, and all other records pertinent to a grant shall be retained for a minimum of 3 years, or longer pending completion and resolution of any audit findings.

FDA and the Comptroller General of the United States or any of their authorized representatives shall have the right of access to any books, documents, papers, or other records of a grantee, sub-grantee, contractor, or subcontractor, which are pertinent to the HHS grant, in order to make audits, examinations, excerpts and transcripts. In accordance with 45 CFR, Part 74.53 and 45 CFR, Part 92, grantees are required to maintain grant accounting records 3 years after the end of a budget period. If any litigation, claim, negotiation, audit or other action involving the records has been started before the expiration of the 3-year period, the records shall be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later. This program has no statutory formula.
This program has no matching requirements.
This program does not have MOE requirements. Awards will be made on a competitive basis. The initial budget period will include a 5 month planning period to support project start-up, relationship-building, and capacity-building. Grant applications will be considered on a noncompetitive basis for years two through four subject to availability of funds, satisfactory progress of the grantee, and a determination that continued funding would be in the best interest of the Federal Government. The budget period in future funding years will consist of three twelve--month periods each year for project implementation. The total project period for an application requesting support should not exceed 48 months. See the following for information on how assistance is awarded/released: Awards are released on an annual basis. None. Tracy Galloway FDA/ CTP
Office of Health Communication and Education
9200 Corporate Blvd., Rockville, Maryland 20850 Email: CTP-OHCE_CoAg@fda.hhs.gov Phone: 301-796-9210 http://www.fda.gov/tobaccoproducts 75-0600-0-1-554. (Cooperative Agreements) FY 12 $0; FY 13 est $0; and FY 14 est $0 The estimated future year range of awards is as follows: FY 2013 $0; FY 2014 $0; FY 2015 $0; FY 2016 $0. Not Applicable. Not Applicable.